Atricure, INC Form 4 insider transactions

AtriCure Director Sven Wehrwein exercised stock options and sold an equal number of common shares for a profit.

AtriCure Director Sven Wehrwein exercised 5,000 stock options and simultaneously sold the same number of common shares for a significant gain.

AtriCure's President and CEO, Michael H. Carrel, reported a charitable gift of 10,000 shares of common stock.

AtriCure Director Regina E. Groves sold 2,452 shares of common stock for approximately $90,290 through a pre-arranged trading plan.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, sold 2,500 shares of common stock for $36.58 per share.

AtriCure, Inc.'s Chief Operating Officer, Douglas J. Seith, acquired 550 shares of common stock at $25.84 per share through the company's Employee Stock Purchase Plan, increasing his total beneficial ownership to 184,113 shares.

AtriCure's Chief Scientific Officer, Vinayak Doraiswamy, acquired 822 shares of common stock at a discounted price of $25.84 per share through the company's Employee Stock Purchase Plan.

AtriCure, Inc.'s Chief Technical Officer, Salvatore Privitera, acquired 822 shares of common stock at a discounted price of $25.84 per share through the company's Employee Stock Purchase Plan.

AtriCure, Inc.'s President and CEO, Michael H. Carrel, acquired 822 shares of common stock at $25.84 per share through the company's Employee Stock Purchase Plan.

AtriCure, Inc.'s Chief Legal Officer, Karl S. Dahlquist, acquired 822 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $25.84 per share.

AtriCure, Inc.'s Chief Scientific Officer, Vinayak Doraiswamy, reported the sale of 2,500 shares of common stock at $33.44 per share on May 28, 2025, under a Rule 10b5-1 trading plan.

Director Maggie Yuen reports acquiring 5,401 shares of AtriCure, Inc. through a restricted stock award.

Director Robert S. White acquired 5,401 shares of AtriCure, Inc. through a restricted stock award.

Director Karen Prange reports acquiring 5,401 shares of AtriCure, Inc. through a restricted stock award that vests in one year.

Director Shlomo Nachman reports acquiring 5,401 shares of AtriCure common stock through a restricted stock award and disposing of 18,511 shares.

Director B. Kristine Johnson reports acquiring 5,401 shares of AtriCure, Inc. through a restricted stock award that vests in one year.

Director Sven Wehrwein reports acquiring 5,401 shares of AtriCure common stock through a restricted stock award.

Director Deborah H. Telman acquired 5,401 shares of AtriCure, Inc. common stock through a restricted stock award.

Director Regina E. Groves reports acquisition of 5,401 shares of AtriCure, Inc. common stock through a restricted stock award.

Director Robert S. White exercised stock options to acquire 10,000 shares of AtriCure, Inc. common stock at a price of $22.62 per share.

AtriCure's CEO, Michael Carrel, reported a gift of 4,000 common stock shares to his children on March 10, 2025, according to a Form 4 filing with the SEC.

Director Karen Prange of AtriCure, Inc. sold 6,100 shares of common stock at an average price of $38.12 on March 5, 2025.

Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc., reports acquisition and disposal of company stock.

Deborah Lee Yount, Chief Human Resources Officer of AtriCure, Inc., reports acquisition and disposal of company stock on March 1, 2025.

Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., reports acquisition and disposal of common stock related to restricted stock and performance share awards.

AtriCure's Chief Operating Officer, Douglas J. Seith, reports acquisition and disposal of company stock related to restricted stock and performance share awards.

AtriCure's Chief Technical Officer, Salvatore Privitera, reports acquisition and disposal of company stock related to restricted stock and performance share awards.

Vinayak Doraiswamy, Chief Scientific Officer of AtriCure, Inc., reports acquisition and disposal of company stock related to restricted stock and performance share awards.

AtriCure's CEO, Michael Carrel, reports acquisition and disposal of company stock, including shares from restricted stock and performance share awards, as well as shares transferred for tax obligations.

AtriCure's Chief Financial Officer, Angela Wirick, reports acquisition and disposal of company stock related to restricted stock and performance share awards.